These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 1633400)
41. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics. Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219 [TBL] [Abstract][Full Text] [Related]
42. Iron-dextran as a magnetic susceptibility contrast agent: flow-related contrast effects in the T2-weighted spin-echo MRI of normal rat and cat brain. White DL; Aicher KP; Tzika AA; Kucharczyk J; Engelstad BL; Moseley ME Magn Reson Med; 1992 Mar; 24(1):14-28. PubMed ID: 1313524 [TBL] [Abstract][Full Text] [Related]
43. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227. Harisinghani MG; Saini S; Weissleder R; Halpern EF; Schima W; Rubin DL; Stillman AE; Sica GT; Small WC; Hahn PF Radiology; 1997 Mar; 202(3):687-91. PubMed ID: 9051017 [TBL] [Abstract][Full Text] [Related]
44. Effect of superparamagnetic iron oxide on tumor-to-liver contrast at T2*-weighted gradient-echo MRI: comparison between 3.0T and 1.5T MR systems. Kim T; Murakami T; Hori M; Onishi H; Tomoda K; Nakamura H J Magn Reson Imaging; 2009 Mar; 29(3):595-600. PubMed ID: 19243054 [TBL] [Abstract][Full Text] [Related]
45. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs. Khangure MS; Hua J Acad Radiol; 1996 Aug; 3 Suppl 2():S458-60. PubMed ID: 8796629 [No Abstract] [Full Text] [Related]
46. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging. Clement O; Frija G; Chambon C; Schouman-Clayes E; Mosnier JF; Poupon MF; Balkau B Radiology; 1991 Jul; 180(1):31-6. PubMed ID: 2052718 [TBL] [Abstract][Full Text] [Related]
47. Soluble-type hepatobiliary contrast agents for MR imaging. de Haën C; Gozzini L J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085 [No Abstract] [Full Text] [Related]
48. Comparison of Gadolinium-BOPTA and Ferucarbotran-enhanced three-dimensional T1-weighted dynamic liver magnetic resonance imaging in the same patient. Wersebe A; Wiskirchen J; Decker U; Schick F; Dietz K; Müller-Schimpfle M; Claussen CD; Pereira PL Invest Radiol; 2006 Mar; 41(3):264-71. PubMed ID: 16481909 [TBL] [Abstract][Full Text] [Related]
49. [Current status of the clinical development of MR contrast media]. Laniado M; Kopp AF Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947 [TBL] [Abstract][Full Text] [Related]
50. The mechanism of ring enhancement in hepatocellular carcinoma on superparamagnetic iron oxide-enhanced T1-weighted images: an investigation into peritumoral Kupffer cells. Tanimoto A; Wakabayashi G; Shinmoto H; Okuda S; Kuribayashi S; Mukai M J Magn Reson Imaging; 2005 Mar; 21(3):230-6. PubMed ID: 15723373 [TBL] [Abstract][Full Text] [Related]
51. [Dynamic MR imaging of liver lesions with superparamagnetic iron oxide (SH-U-555A)]. Saito K; Ishida J; Ito N; Kakizaki D; Kotake F; Abe K Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Feb; 61(3):84-8. PubMed ID: 11265126 [TBL] [Abstract][Full Text] [Related]
54. MR evaluation of the glomerular homing of magnetically labeled mesenchymal stem cells in a rat model of nephropathy. Hauger O; Frost EE; van Heeswijk R; Deminière C; Xue R; Delmas Y; Combe C; Moonen CT; Grenier N; Bulte JW Radiology; 2006 Jan; 238(1):200-10. PubMed ID: 16373768 [TBL] [Abstract][Full Text] [Related]
55. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging. Choi JY; Kim MJ; Kim JH; Kim SH; Ko HK; Lim JS; Oh YT; Chung JJ; Yoo HS; Lee JT; Kim KW Eur J Radiol; 2006 Oct; 60(1):84-90. PubMed ID: 16920315 [TBL] [Abstract][Full Text] [Related]
56. [Superparamagnetic iron oxide particles: what value has the T1 effect in the MR diagnosis of focal liver lesions?]. Urhahn R; Adam G; Busch N; Chen JH; Euringer W; Günther RW Rofo; 1996 Oct; 165(4):364-70. PubMed ID: 8963049 [TBL] [Abstract][Full Text] [Related]
57. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Chambon C; Clement O; Le Blanche A; Schouman-Claeys E; Frija G Magn Reson Imaging; 1993; 11(4):509-19. PubMed ID: 8316064 [TBL] [Abstract][Full Text] [Related]
58. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging. Tang Y; Yamashita Y; Arakawa A; Namimoto T; Mitsuzaki K; Abe Y; Katahira K; Takahashi M AJR Am J Roentgenol; 1999 Jun; 172(6):1547-54. PubMed ID: 10350287 [TBL] [Abstract][Full Text] [Related]